Coagulation factor VIII (Guangdong Danxia Biopharm)

人凝血因子VIII（广东丹霞生物制药）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCoagulation factor VIII (Guangdong Danxia Biopharm)

Drug Alias Name人凝血因子VIII生物仿制药（广东丹霞生物制药）

ClassificationBiologics > Protein drugs > Non-recombinant coagulation factorBiologics > Blood components > Non-recombinant coagulation factorBiologics > Blood components

Mechanisms of ActionCoagulation factor VIII replacementsCoagulation factor X stimulantsBlood coagulation pathway activation

TargetsCoagulation factor X

Therapy Area/IndicationsHemorrhageHemophilia A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 3 Clinical)

Highest Status in ChinaPending

Originator CompaniesGuangdong Danxia Biological Pharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGuangdong Danxia Biological Pharmaceutical Co Ltd

Active IndicationsN/A

Inactive IndicationsHemorrhageHemophilia A

Other Information

ATC CodeB02BD02